BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance
暂无分享,去创建一个
Hans Clevers | Jos Jonkers | Piet Borst | Norman Sachs | Arno Velds | H. Clevers | Norman Sachs | P. Borst | J. Jonkers | E. Gogola | A. Duarte | S. Rottenberg | M. van de Ven | A. Velds | S. Annunziato | Sven Rottenberg | Alexandra A Duarte | Ewa Gogola | Marco Barazas | Stefano Annunziato | Julian R de Ruiter | Sohvi Blatter | Julia M Houthuijzen | Marieke van de Ven | J. M. Houthuijzen | M. Barazas | Sohvi Blatter | Julian R de Ruiter | J. Houthuijzen
[1] Jos Jonkers,et al. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland , 2016, Genes & development.
[2] Alan Ashworth,et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Peter Bouwman,et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition , 2015, Nature.
[4] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[5] Jing Zhou,et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids , 2015, Nature Communications.
[6] S. Cantor,et al. Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells , 2016, Nature.
[7] Heng Li. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.
[8] P. Borst,et al. Drug resistance in the mouse cancer clinic. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[9] Grant W. Brown,et al. HELB Is a Feedback Inhibitor of DNA End Resection. , 2016, Molecular cell.
[10] D. Adams,et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers , 2010, Nature Structural &Molecular Biology.
[11] Marc Bickle,et al. Screening out irrelevant cell-based models of disease , 2016, Nature Reviews Drug Discovery.
[12] J. Peterse,et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer , 2007, Proceedings of the National Academy of Sciences.
[13] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[14] Hans Clevers,et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.
[15] B. van Steensel,et al. Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.
[16] David C. Jones,et al. Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.
[17] Takanori Kanai,et al. Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids , 2015, Nature Medicine.
[18] A. Ashworth,et al. Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study , 2013, Clinical Cancer Research.
[19] Jos Jonkers,et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer , 2007, Proceedings of the National Academy of Sciences.
[20] J. Jonkers,et al. Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer. , 2016, Cold Spring Harbor symposia on quantitative biology.
[21] Hans Clevers,et al. Sequential cancer mutations in cultured human intestinal stem cells , 2015, Nature.
[22] H. Clevers,et al. Single Lgr5 stem cells build cryptvillus structures in vitro without a mesenchymal niche , 2009, Nature.
[23] A. Lau,et al. Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin , 2008, Clinical Cancer Research.
[24] H. Clevers,et al. Controlled gene expression in primary Lgr5 organoid cultures , 2011, Nature Methods.
[25] M. Leist,et al. Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy , 2014, Cell Death and Disease.
[26] L. Wessels,et al. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance. , 2015, Cancer research.
[27] Jeremy M. Stark,et al. 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.
[28] L. Ailles,et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences , 2000, Nature Genetics.
[29] P. Borst,et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.
[30] Joseph M. Negri,et al. The role of tumour–stromal interactions in modifying drug response: challenges and opportunities , 2013, Nature Reviews Drug Discovery.
[31] John W. Cassidy,et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.
[32] Data production leads,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .
[33] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[34] Zhiping Weng,et al. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. , 2015, Human gene therapy.
[35] Hans Clevers,et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.
[36] Anirudh Prahallad,et al. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. , 2014, Cell reports.
[37] Andrew J Ewald,et al. Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. , 2008, Developmental cell.
[38] Jos Jonkers,et al. CopywriteR: DNA copy number detection from off-target sequence data , 2015, Genome Biology.
[39] Shridar Ganesan,et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.
[40] A. Berns,et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.
[41] Martin Renqiang Min,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .